National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer ID6589 Consultation on suggested remit, draft scope and provisional ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer TA1138 2 March 2026 2 March 2026 ...
The National Institute for Health and Care Excellence

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy ...
The National Institute for Health and Care Excellence

Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 ...